Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.48 |
| ▸ | LPL | P06858 | 3/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228 | 0.83 | LIPG (0.54) | LIPGLPLP4HBF11F2 | |
| SCHEMBL22871651 | 0.83 | LIPG (0.54) | LIPGLPLKEAP1NFE2L2P4HB | |
| SCHEMBL21383623 | 0.83 | LIPG (0.53) | LIPGLPLDGAT1KEAP1NFE2L2 | |
| SCHEMBL16196202 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LIPGLPL | |
| SCHEMBL16342895 | 0.83 | KMT2A (0.58) | ALDH1A1L3MBTL1LIPGLPLDGAT1 | |
| SCHEMBL14709908 | 0.82 | LIPG (0.49) | LIPGLPLDGAT1KEAP1NFE2L2 | |
| SCHEMBL21383621 | 0.82 | LIPG (0.54) | LIPGLPLKEAP1NFE2L2P4HB | |
| SCHEMBL1240002 | 0.81 | LIPG (0.55) | LIPGLPLP4HBF11F2 | |
| SCHEMBL14934909 | 0.81 | KEAP1 (0.55) | LIPGLPLDGAT1KEAP1NFE2L2 | |
| SCHEMBL16030765 | 0.81 | KEAP1 (0.55) | LIPGLPLDGAT1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225623-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9655904-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2467377-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9126940-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2467377-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011022508-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | ALDH1A1 1667/4885MAPK1 1690/4885L3MBTL1 1982/4885 |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | ALDH1A1 2553/4885MAPK1 1530/4885L3MBTL1 1591/4885 |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | ALDH1A1 1667/4885MAPK1 1690/4885L3MBTL1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.